Integra LifeSciences Holdings Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Integra LifeSciences Holdings Corporation
As Korean firms report quarterly earnings, Hanmi is stepping up the development of obesity drugs, Daewoong unveils plans to boost sales of in-house new drugs, GC Biopharma’s immunoglobulin undergoes the US approval process and Ildong has set up a new R&D-focused subsidiary.
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
- Medical Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- ACell, Inc.
- Arkis BioSciences
- Ascension Orthopedics
- Confluent Surgical, Inc.
- Derma Sciences, Inc.
- IsoTis Orthobiologics, Inc.
- Minnesota Scientific
- Newdeal SA
- Omni-Tract Surgical
- Innovative Spinal Technologies Inc.
- Rebound Therapeutics
- Surgical Innovation Associates
- TEI Biosciences Inc.
- TEI Medical Inc.
- Terragraphix, Inc.
- TGX Medical
- TGX Medical Systems, LLC
- MCF I LP THX Medical System LLC Holdings, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.